Subscribe to our Email Alerts

Investor Fact Sheet

Company Name: Amplia Therapeutics Limited (ACN 165 160 841)

Business Description:

Amplia Therapeutics Limited (ASX: ATX) is an Australian pharmaceutical company that is advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer immunology and Innate has a particular development focus in pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF).


Shares on Issue: 194,005,536 Fully Paid Ordinary Shares
Options on Issue:

25,439,421 ATXO Listed Options - Ex Price $0.28, Expiry 31 December 2023

7,377,165 Unlisted Options (at varying exercise prices and expiry dates)

 

Target Market Determination:
ATXO Options

The Company has made a Target Market Determination in respect of ATXO Listed Options - Ex Price $0.28, Expiry 31 December 2023 which can be viewed here.


Market Listings:

Australian Securities Exchange (ASX Code: ATX)


Directors:

Dr Warwick Tong, Chairman, Non-Executive Director
Dr John Lambert, CEO and Managing Director
Dr Robert Peach, Independent Non-Executive Director
Dr Christopher Burns, Non-Executive Director
Ms Jane Bell, Independend Non-Executive Director


Management:

Dr John Lambert, CEO and Managing Director
Mr Hamish George, Chief Financial Officer
Dr Rhiannon Jones, Chief Operating Officer
Mr Andrew Cooke, Company Secretary


Registered Office:

Level 17
350 Queen Street
Melbourne VIC 3000
Australia


Auditors:

Grant Thornton Audit Pty
GPO Box 4736
Melbourne 3001
Australia